Patent Analysis
Patent Analysis
Sale
The circulating tumor cells market was valued at USD 11.5 billion in 2023. It is expected to grow at a CAGR of 12.5% during the forecast period of 2024-2032 and attain a market value of USD 33.19 billion in 2032.
The market value is impacted by the increasing use of such platforms and ongoing technological advancements in this field. There has been a significant increase in number of patent applications associated with circulating tumor cells, driven by the need for sophisticated monitoring and diagnostic instruments and the rising incidence of different forms of cancer in the world.
The Global Circulating Tumor Cells Patent Landscape Report provides a comprehensive and in-depth analysis of the patents in this growing industry. The key sections captured in the report for circulating tumor cells includes a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It consists of the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within circulating tumor cell technologies.
Biological isolation is a protein-based technique that mostly relies on specific markers that are picked up by aptamers or other particles like antibodies. Positive isolation involves enriching the sample with desired cells, while negative isolation involves depleting the sample with unwanted cells. Therefore, such techniques have a significant impact on the patent landscape.
Circulating tumor cells refer to the cancer cells that have been separated from the main tumor and are now moving through the blood. It acts as an indicator for the existence of cancer and its propensity to spread to other bodily regions. CTCs are an essential focus in cancer diagnostics and research because they can reveal important information about the course of the disease, how well a treatment is working, and how long the cancer may last.
The circulating tumor cells market continues to evolve, driven by healthcare professionals seeking less or non-invasive diagnostic alternatives for detection. It is an effective substitute for conventional biopsy techniques as well. Also, CTC’s broader range of applications is fueling market expansion, including early cancer detection, prognosis, treatment monitoring, and comprehension of metastatic processes.
Increasing Technological Advancements in Circulating Tumor Cells is Expected to Boost the Market Growth
Advances in technological innovations in CTC detection and isolation technologies significantly enhance the market's growth, improving patient outcomes and fueling market growth. These advancements improve the accuracy and reliability of CTC analysis, making it more widely adopted in clinical and research settings.
For instance, in 2021, Menarini Silicon Biosystems, a leader in single-cell and liquid biopsy technologies, announced the release of the highly automated DEPArrayTM PLUS*. Integrated with nine fluorescent channels, it can precisely isolate and characterize CTCs using imaging and microfluidic technologies. The advent of such technologically advanced products is expected to impact the patent landscape as companies apply for patent applications.
Rising Demand for Non-Invasive Diagnostic Methods is Expected to Propel the Circulating Tumor Cells Industry Growth
The need for CTC analysis is fueled by the growing inclination for non-invasive diagnostic methods as it offer vital cancer-related data via straightforward blood tests. Compared to conventional tissue biopsies, this method minimizes patient discomfort and risk, which will encourage broader use of the technique in clinical practice.
The report provides an in-depth analysis of the patents in this field by the following segmentation -
Breakup by Product
Breakup by Technology
The breakup based on technology includes CTC detection and enrichment methods, CTC direct detection methods and CTC analysis. CTC detection and enrichment method involves size-based filtration, immunomagnetic separation, and microfluidics to separate and identify circulating tumor cells from blood samples. These improve the precision and effectiveness of CTC detection while offering insightful information about the course of cancer and the effectiveness of treatment.
The detailed technological data will be provided for all specified segments classified in this report.
The United States is one of the leading jurisdictions for circulating tumor cells patents, having around 150,000 patents. The presence of a well-established healthcare infrastructure, a robust legal framework and prominent research institutions engaged in innovations contributes to the patent landscape significantly.
China, with a significant portion of the global geriatric population, is another vital jurisdiction and is witnessing rapid growth in patent filings. The expanding healthcare landscape in the region contributes to the evolving research capabilities, thereby influencing a surge in patent applications. The rising incidence of cancer also fuels market growth in the region.
Among the players with circulating tumor cells patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:
Bristol Myers Squibb Co.
An international biopharmaceutical business with a focus on cutting-edge cancer therapies. The company's goal is to increase the accuracy of cancer diagnosis and treatment outcomes by actively studying and applying circulating tumor cells (CTCs) patents.
F. Hoffmann La Roche
A world leader in drugs and diagnostics, this company is renowned for creating cutting-edge cancer therapies and diagnostic tools. The business improves cancer detection, prognosis, and monitoring by utilizing circulating tumor cell (CTC) technology, which supports personalized medicine and better patient outcomes in oncology.
Other companies include Univ California, Genentech INC, Univ Pennsylvania, Univ Texas, Univ Leland Stanford Junior, Massachusetts Inst Technology, Univ Johns Hopkins, Harvard College, Amgen INC, Zymogenetics INC, Human Genome Sciences INC, Millennium Pharm INC, Dana Farber Cancer Inst INC, Epic Sciences Inc., Ventana Med Syst Inc. (Roche Group), Curis Inc. Massachusetts Gen Hospital, Univ Washington, Gen Hospital Corp, Alnylam Pharmaceuticals INC, Immunomedics INC, Centre Nat Rech Scient, among others.
The Global Circulating Tumor Cells Patent Report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by:
Scope of the Report | Details |
Analysis by Product Type |
|
Analysis by Sit Outlook |
|
Analysis by Application |
|
Key Players Mentioned |
|
Geographies Covered |
|
Global Cancer Tumor Profiling Market
Global Brain Tumor Treatment Market
Global Cell Separation Technology Market
Neuroendocrine Tumours Treatment Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Introduction
2 Executive Summary
3 Global Circulating Tumor Cells Market Overview
3.1 Global Circulating Tumor Cells Market Historical Value (2017-2023)
3.2 Global Circulating Tumor Cells Market Forecast Value (2024-2032)
4 Global Circulating Tumor Cells Market Segmentation
4.1 Global Circulating Tumor Cells Market Share by Product
4.1.1 Market Overview
4.1.2 Kits and Reagents
4.1.3 Blood Collection Tubes
4.1.4 Devices/Systems
4.2 Global Circulating Tumor Cells Market Share by Technology
4.2.1 Market Overview
4.2.2 CTC Detection and Enrichment Methods
4.2.3 CTC Direct Detection Methods
4.3 Global Circulating Tumor Cells Market Share by End User
4.3.1 Market Overview
4.3.2 Hospitals
4.3.3 Research Institute
4.3.4 Diagnostic Centre
4.4 Others Global Circulating Tumor Cells Market Share by Application
4.4.1 Market Overview
4.4.2 Clinical
4.4.3 Research
5 Global Market Dynamics
5.1 Market Drivers and Constraints
5.2 Porter’s Five Forces Analysis
5.3 PESTEL Analysis
5.4 Industry Events, Initiatives, and Trends
5.5 Value Chain Analysis
6 Global Circulating Tumor Cells Patent Landscape Analysis
6.1 Patent Distribution by Publication Year
6.2 Patent Distribution by Application Year
6.3 Patent Distribution by Priority Year
6.4 Analysis by Type of Patent
6.4.1 Granted Patents
6.4.2 Patent Application
6.4.3 Amended Application
6.4.4 Search Report
6.5 Analysis by Legal Status
6.5.1 Active
6.5.2 Pending
6.5.3 Expired/Discontinued
6.6 Analysis by Patent Jurisdiction
6.7 Analysis by Patent Age
6.8 Analysis by Cooperative Patent Classification (CPC) Codes
6.9 Average Time to Publish a Patent
6.9.1 By Entities
6.9.2 By Jurisdiction
6.9.3 By Technology
6.10 Analysis by Type of Entity (Academic and Non-Academic)
6.11 Analysis by Top Applicants
6.12 Analysis by Top Inventors
7 Global Circulating Tumor Cells Patent Analysis by Technology
7.1 Total Patents by Top Technologies
7.2 Time Evolution of Patents by Technology
7.3 Emerging Technologies
7.4 Patent Segmentation, By Method
7.4.1 Time Evolution by Number of Patents
7.4.2 Time Evolution by Number of Patent Families
7.4.3 Analysis by Type of Entity (Academic vs Non-Academic)
7.4.4 Analysis by Top Applicants
7.4.5 Analysis by Top Inventors
7.5 Patent Segmentation, By Product
*Complete technology list will be provided in the report.
8 EMR Patent Valuation Analysis
8.1 Assessment Methodology
8.2 High Value Patents
8.3 Medium Value Patents
8.4 Low Value Patents
9 Global Circulating Tumor Cells – Top 10 Players Patent Analysis
9.1 Top 10 Entities by Number of Patents
9.2 Analysis by Publication Year
9.3 Analysis by Application Year
9.4 Analysis by Priority Year
9.5 Analysis by Type of Patent
9.6 Analysis by Jurisdiction
9.7 Analysis by Cooperative Patent Classification (CPC) Codes
9.8 Analysis by Source of Innovation
9.9 Analysis by Forward and Backward Citations
9.10 Analysis by Legal Status
9.11 Analysis by Patent Age
9.12 Analysis by Key Inventors
9.13 Entity Dynamics
9.13.1 Analysis by Type of Player (Academic vs Non-Academic)
9.13.2 Analysis by Collaboration
9.13.3 Analysis by Technology
9.13.4 Newcomers
9.13.4.1 Start-up Companies
9.13.4.2 Established Companies
10 Patent Profile of Key Players
10.1 Genentech Inc
10.1.1 Product Portfolio
10.1.2 Patent Portfolio by Patent Families
10.1.3 Time Evolution of Patents
10.1.4 Geographical Patent Coverage
10.1.5 Patent Analysis by Technology
10.1.6 Patent News and Developments
10.1.7 Financial Analysis
10.1.8 SWOT Analysis
10.2 F. Hoffmann-La Roche AG
10.3 Epic Sciences Inc .
10.4 Ventana Med Syst Inc. (Roche Group )
10.5 Curis Inc .
11 Future Trends
12 Global Circulating Tumor Cells Market Landscape (Additional Insight) *
12.1 Global Circulating Tumor Cells: Developers Landscape
12.1.1 Analysis by Year of Establishment
12.1.2 Analysis by Company Size
12.1.3 Analysis by Region
12.2 Global Circulating Tumor Cells: Product Landscape
12.2.1 Analysis by Product
12.2.2 Analysis by Technology
12.2.3 Analysis by Application
*Additional insights are not provided in the standard report.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.